Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Carcinoma, Non-Small-Cell Lung | 43 | 2023 | 5221 | 3.760 |
Why?
|
Lung Neoplasms | 60 | 2023 | 13102 | 3.500 |
Why?
|
Radiosurgery | 20 | 2023 | 1329 | 3.140 |
Why?
|
Radiation Oncology | 5 | 2022 | 555 | 1.630 |
Why?
|
Artificial Intelligence | 8 | 2024 | 2214 | 1.550 |
Why?
|
Radiation Pneumonitis | 4 | 2023 | 104 | 1.350 |
Why?
|
Radiation Injuries | 3 | 2023 | 1180 | 1.280 |
Why?
|
Radiotherapy | 6 | 2019 | 1533 | 1.160 |
Why?
|
Cone-Beam Computed Tomography | 3 | 2020 | 450 | 1.050 |
Why?
|
Tachycardia, Ventricular | 7 | 2022 | 1273 | 1.010 |
Why?
|
Heart Diseases | 3 | 2022 | 2788 | 0.910 |
Why?
|
Radiation Dosage | 12 | 2022 | 1928 | 0.840 |
Why?
|
Tumor Burden | 9 | 2020 | 1915 | 0.810 |
Why?
|
Thoracic Neoplasms | 1 | 2023 | 268 | 0.790 |
Why?
|
Radiotherapy Planning, Computer-Assisted | 10 | 2023 | 1624 | 0.780 |
Why?
|
Coronary Vessels | 5 | 2022 | 3107 | 0.640 |
Why?
|
Collagen Diseases | 1 | 2017 | 34 | 0.620 |
Why?
|
Small Cell Lung Carcinoma | 2 | 2020 | 388 | 0.620 |
Why?
|
Urologic Diseases | 2 | 2018 | 244 | 0.600 |
Why?
|
Equipment and Supplies | 1 | 2020 | 281 | 0.600 |
Why?
|
Equipment Failure | 1 | 2018 | 578 | 0.540 |
Why?
|
Neoplasm Staging | 18 | 2021 | 11031 | 0.530 |
Why?
|
Salvage Therapy | 3 | 2018 | 1275 | 0.530 |
Why?
|
Tomography, X-Ray Computed | 20 | 2024 | 20129 | 0.520 |
Why?
|
Peanut Hypersensitivity | 3 | 2022 | 163 | 0.490 |
Why?
|
Heart | 5 | 2023 | 4467 | 0.470 |
Why?
|
Pneumonectomy | 2 | 2018 | 1094 | 0.470 |
Why?
|
Neoplasms | 9 | 2023 | 21683 | 0.460 |
Why?
|
Lymphatic Metastasis | 2 | 2019 | 2924 | 0.440 |
Why?
|
Pacemaker, Artificial | 1 | 2018 | 816 | 0.440 |
Why?
|
Humans | 129 | 2024 | 744343 | 0.420 |
Why?
|
Retrospective Studies | 34 | 2023 | 77449 | 0.420 |
Why?
|
Urinary Bladder | 4 | 2014 | 1172 | 0.400 |
Why?
|
Cystectomy | 2 | 2014 | 686 | 0.400 |
Why?
|
Natural Language Processing | 4 | 2023 | 1041 | 0.390 |
Why?
|
Catheter Ablation | 5 | 2022 | 2758 | 0.390 |
Why?
|
Muscle, Smooth | 1 | 2014 | 934 | 0.370 |
Why?
|
Methylenetetrahydrofolate Reductase (NADPH2) | 1 | 2011 | 284 | 0.370 |
Why?
|
Adenocarcinoma | 7 | 2022 | 6364 | 0.360 |
Why?
|
Radiotherapy, Intensity-Modulated | 3 | 2021 | 806 | 0.350 |
Why?
|
Aged | 43 | 2022 | 163280 | 0.350 |
Why?
|
Aged, 80 and over | 24 | 2020 | 57776 | 0.350 |
Why?
|
ras Proteins | 1 | 2014 | 1060 | 0.340 |
Why?
|
Urinary Bladder Neoplasms | 2 | 2014 | 2245 | 0.340 |
Why?
|
Vascular Diseases | 1 | 2017 | 1161 | 0.340 |
Why?
|
Defibrillators, Implantable | 1 | 2018 | 1440 | 0.340 |
Why?
|
Esophageal Neoplasms | 3 | 2023 | 1583 | 0.330 |
Why?
|
Vulvar Neoplasms | 1 | 2010 | 272 | 0.310 |
Why?
|
Middle Aged | 44 | 2023 | 213383 | 0.300 |
Why?
|
Male | 55 | 2023 | 350118 | 0.280 |
Why?
|
Uremia | 4 | 1992 | 201 | 0.280 |
Why?
|
Combined Modality Therapy | 8 | 2022 | 8642 | 0.270 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2021 | 3255 | 0.270 |
Why?
|
Point Mutation | 1 | 2011 | 1623 | 0.260 |
Why?
|
Urethra | 2 | 2018 | 408 | 0.260 |
Why?
|
Models, Statistical | 2 | 2019 | 5102 | 0.260 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 4 | 2017 | 1692 | 0.250 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2020 | 9959 | 0.250 |
Why?
|
Practice Guidelines as Topic | 2 | 2020 | 7279 | 0.250 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 6 | 2022 | 11524 | 0.250 |
Why?
|
Radiotherapy Dosage | 8 | 2023 | 2879 | 0.250 |
Why?
|
Female | 49 | 2023 | 380194 | 0.240 |
Why?
|
Lung | 9 | 2023 | 9856 | 0.240 |
Why?
|
Clinical Trials as Topic | 1 | 2020 | 7913 | 0.240 |
Why?
|
Thorax | 2 | 2024 | 547 | 0.230 |
Why?
|
Temporal Muscle | 1 | 2023 | 37 | 0.230 |
Why?
|
Kaplan-Meier Estimate | 6 | 2019 | 6538 | 0.230 |
Why?
|
Hypertension | 2 | 2022 | 8480 | 0.230 |
Why?
|
Fluorodeoxyglucose F18 | 2 | 2016 | 2016 | 0.230 |
Why?
|
Venous Thromboembolism | 1 | 2016 | 1671 | 0.230 |
Why?
|
Growth Charts | 1 | 2023 | 61 | 0.230 |
Why?
|
Four-Dimensional Computed Tomography | 2 | 2014 | 145 | 0.220 |
Why?
|
Carcinoma | 1 | 2014 | 2375 | 0.220 |
Why?
|
Preoperative Care | 2 | 2011 | 2250 | 0.210 |
Why?
|
Delivery of Health Care | 1 | 2020 | 5319 | 0.210 |
Why?
|
Esophagitis | 1 | 2023 | 152 | 0.210 |
Why?
|
Multivariate Analysis | 6 | 2018 | 12245 | 0.210 |
Why?
|
Coronary Artery Disease | 1 | 2022 | 6487 | 0.210 |
Why?
|
Prostatic Neoplasms | 4 | 2023 | 11124 | 0.210 |
Why?
|
Proto-Oncogene Proteins | 1 | 2014 | 4554 | 0.210 |
Why?
|
Carcinoma, Transitional Cell | 1 | 2008 | 808 | 0.200 |
Why?
|
Medical Oncology | 3 | 2023 | 2265 | 0.200 |
Why?
|
Survival Analysis | 4 | 2020 | 10252 | 0.200 |
Why?
|
Mutation | 7 | 2017 | 29786 | 0.200 |
Why?
|
Rectal Neoplasms | 1 | 2010 | 1206 | 0.200 |
Why?
|
Neoadjuvant Therapy | 5 | 2016 | 2728 | 0.200 |
Why?
|
Diagnosis, Computer-Assisted | 2 | 2018 | 719 | 0.190 |
Why?
|
Radiation Tolerance | 3 | 2018 | 486 | 0.190 |
Why?
|
Treatment Outcome | 18 | 2022 | 63114 | 0.190 |
Why?
|
Desensitization, Immunologic | 3 | 2022 | 483 | 0.190 |
Why?
|
Carcinoma, Squamous Cell | 4 | 2016 | 4034 | 0.190 |
Why?
|
Radiopharmaceuticals | 1 | 2011 | 2645 | 0.190 |
Why?
|
Cefazolin | 1 | 2021 | 96 | 0.190 |
Why?
|
Calcitriol | 2 | 1992 | 298 | 0.190 |
Why?
|
Adult | 28 | 2020 | 214055 | 0.190 |
Why?
|
Imaging, Three-Dimensional | 4 | 2014 | 4042 | 0.180 |
Why?
|
Ribosomal Proteins | 2 | 2017 | 360 | 0.180 |
Why?
|
Fluoroscopy | 2 | 2014 | 924 | 0.170 |
Why?
|
Prognosis | 10 | 2022 | 29063 | 0.170 |
Why?
|
Phantoms, Imaging | 4 | 2022 | 2480 | 0.170 |
Why?
|
Cardiomyopathies | 2 | 2021 | 1912 | 0.160 |
Why?
|
Neutrons | 1 | 2018 | 76 | 0.160 |
Why?
|
Penicillins | 1 | 2021 | 380 | 0.160 |
Why?
|
Arrhythmias, Cardiac | 4 | 2023 | 2268 | 0.160 |
Why?
|
Sarcopenia | 1 | 2023 | 368 | 0.160 |
Why?
|
Laryngeal Neoplasms | 1 | 2022 | 512 | 0.160 |
Why?
|
Ablation Techniques | 1 | 2021 | 249 | 0.160 |
Why?
|
Carcinoma, Adenoid Cystic | 1 | 2020 | 252 | 0.160 |
Why?
|
Neoplasm Recurrence, Local | 5 | 2023 | 9239 | 0.160 |
Why?
|
Respiration | 5 | 2017 | 1653 | 0.150 |
Why?
|
Algorithms | 8 | 2024 | 13881 | 0.150 |
Why?
|
Stereotaxic Techniques | 1 | 2020 | 536 | 0.150 |
Why?
|
Pneumonia | 2 | 2020 | 2133 | 0.150 |
Why?
|
Diagnostic Imaging | 3 | 2019 | 3507 | 0.150 |
Why?
|
Follow-Up Studies | 7 | 2019 | 39050 | 0.150 |
Why?
|
Pulmonary Veins | 1 | 2023 | 761 | 0.150 |
Why?
|
Cohort Studies | 7 | 2021 | 40561 | 0.150 |
Why?
|
Larynx | 1 | 2022 | 494 | 0.150 |
Why?
|
Angina Pectoris | 1 | 2021 | 977 | 0.140 |
Why?
|
Myocardial Revascularization | 1 | 2021 | 841 | 0.140 |
Why?
|
Image Processing, Computer-Assisted | 5 | 2024 | 8949 | 0.140 |
Why?
|
Survival Rate | 4 | 2018 | 12788 | 0.140 |
Why?
|
Carcinoma, Large Cell | 1 | 2016 | 113 | 0.140 |
Why?
|
Death | 1 | 2021 | 678 | 0.140 |
Why?
|
Antibiotic Prophylaxis | 1 | 2021 | 639 | 0.130 |
Why?
|
Electrophysiology | 1 | 2019 | 1308 | 0.130 |
Why?
|
Osteopontin | 1 | 2017 | 296 | 0.130 |
Why?
|
Carcinoma in Situ | 1 | 2021 | 806 | 0.130 |
Why?
|
Cytoplasmic Granules | 1 | 2018 | 610 | 0.130 |
Why?
|
Food Hypersensitivity | 1 | 2022 | 622 | 0.130 |
Why?
|
Disease-Free Survival | 3 | 2021 | 6895 | 0.130 |
Why?
|
Ribonucleoproteins | 1 | 2018 | 381 | 0.130 |
Why?
|
Gastrointestinal Diseases | 1 | 2023 | 1170 | 0.130 |
Why?
|
Immunoconjugates | 1 | 2022 | 901 | 0.120 |
Why?
|
Cranial Irradiation | 1 | 2017 | 401 | 0.120 |
Why?
|
Incidence | 6 | 2021 | 20947 | 0.120 |
Why?
|
Medical Informatics | 1 | 2021 | 745 | 0.120 |
Why?
|
Positron-Emission Tomography | 6 | 2019 | 6234 | 0.120 |
Why?
|
Radiotherapy, Conformal | 1 | 2017 | 548 | 0.120 |
Why?
|
Radiometry | 2 | 2017 | 800 | 0.120 |
Why?
|
Evaluation Studies as Topic | 1 | 2016 | 1681 | 0.120 |
Why?
|
Protein Kinase Inhibitors | 2 | 2023 | 5535 | 0.120 |
Why?
|
Clinical Trials, Phase II as Topic | 2 | 2014 | 629 | 0.120 |
Why?
|
Polymorphism, Single Nucleotide | 2 | 2020 | 15519 | 0.120 |
Why?
|
Neoplasm Invasiveness | 2 | 2014 | 3616 | 0.120 |
Why?
|
Predictive Value of Tests | 5 | 2018 | 15076 | 0.110 |
Why?
|
Ribosomes | 1 | 2017 | 500 | 0.110 |
Why?
|
Neoplasm Metastasis | 6 | 2022 | 4851 | 0.110 |
Why?
|
Risk Factors | 11 | 2022 | 72290 | 0.110 |
Why?
|
Observer Variation | 2 | 2016 | 2593 | 0.110 |
Why?
|
Fellowships and Scholarships | 1 | 2021 | 1076 | 0.110 |
Why?
|
Lung Diseases | 1 | 2023 | 1886 | 0.110 |
Why?
|
Prostate | 2 | 2023 | 1774 | 0.110 |
Why?
|
Renal Dialysis | 2 | 1992 | 1786 | 0.110 |
Why?
|
Magnetic Resonance Spectroscopy | 4 | 2023 | 3760 | 0.110 |
Why?
|
Radiotherapy, Adjuvant | 2 | 2015 | 1770 | 0.110 |
Why?
|
GTP-Binding Proteins | 1 | 2017 | 970 | 0.110 |
Why?
|
Drug Hypersensitivity | 1 | 2021 | 884 | 0.110 |
Why?
|
Ubiquitination | 1 | 2017 | 1012 | 0.100 |
Why?
|
Administration, Oral | 5 | 2022 | 3913 | 0.100 |
Why?
|
Thoracic Wall | 1 | 2014 | 203 | 0.100 |
Why?
|
United States Food and Drug Administration | 1 | 2020 | 1584 | 0.100 |
Why?
|
Brain Neoplasms | 4 | 2017 | 8863 | 0.100 |
Why?
|
Lung Diseases, Interstitial | 1 | 2020 | 808 | 0.100 |
Why?
|
Radiographic Image Interpretation, Computer-Assisted | 1 | 2018 | 1184 | 0.100 |
Why?
|
Ubiquitin | 1 | 2017 | 852 | 0.100 |
Why?
|
Fanconi Anemia Complementation Group D2 Protein | 1 | 2011 | 148 | 0.100 |
Why?
|
Pattern Recognition, Automated | 2 | 2014 | 1005 | 0.100 |
Why?
|
Neoplasm Proteins | 3 | 2023 | 3703 | 0.090 |
Why?
|
Ultrasonography, Prenatal | 1 | 2018 | 1695 | 0.090 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2014 | 841 | 0.090 |
Why?
|
Reproducibility of Results | 7 | 2018 | 19905 | 0.090 |
Why?
|
Proportional Hazards Models | 3 | 2015 | 12354 | 0.090 |
Why?
|
Stress, Physiological | 1 | 2018 | 1403 | 0.090 |
Why?
|
Cold Temperature | 1 | 2013 | 772 | 0.090 |
Why?
|
Heart Ventricles | 1 | 2022 | 3821 | 0.090 |
Why?
|
Erythroid Precursor Cells | 2 | 2008 | 218 | 0.090 |
Why?
|
Pleural Neoplasms | 1 | 2015 | 607 | 0.090 |
Why?
|
Multicenter Studies as Topic | 1 | 2014 | 1677 | 0.090 |
Why?
|
Myocardial Ischemia | 1 | 2020 | 2148 | 0.090 |
Why?
|
Magnetic Resonance Imaging | 5 | 2023 | 35421 | 0.090 |
Why?
|
Chemotherapy, Adjuvant | 2 | 2015 | 3479 | 0.090 |
Why?
|
Protein Biosynthesis | 1 | 2017 | 2126 | 0.090 |
Why?
|
Head and Neck Neoplasms | 1 | 2023 | 2734 | 0.090 |
Why?
|
Allergens | 3 | 2022 | 1320 | 0.090 |
Why?
|
RecQ Helicases | 1 | 2009 | 54 | 0.080 |
Why?
|
Insulin | 4 | 1992 | 6580 | 0.080 |
Why?
|
Organoplatinum Compounds | 1 | 2010 | 408 | 0.080 |
Why?
|
Parathyroid Hormone | 3 | 1992 | 1801 | 0.080 |
Why?
|
Hematopoiesis | 2 | 2011 | 2072 | 0.080 |
Why?
|
SEER Program | 2 | 2010 | 1508 | 0.080 |
Why?
|
Mesothelioma | 1 | 2015 | 818 | 0.080 |
Why?
|
Calcium | 1 | 2022 | 5756 | 0.080 |
Why?
|
E1A-Associated p300 Protein | 1 | 2009 | 131 | 0.080 |
Why?
|
Spinal Cord Compression | 1 | 2010 | 235 | 0.080 |
Why?
|
Endpoint Determination | 1 | 2011 | 601 | 0.080 |
Why?
|
Carcinoma, Renal Cell | 1 | 2023 | 3143 | 0.080 |
Why?
|
Kidney Failure, Chronic | 4 | 1997 | 2538 | 0.080 |
Why?
|
Carbohydrate Metabolism | 1 | 1989 | 264 | 0.080 |
Why?
|
ROC Curve | 2 | 2017 | 3527 | 0.080 |
Why?
|
Time Factors | 5 | 2019 | 40075 | 0.080 |
Why?
|
Prospective Studies | 6 | 2023 | 53288 | 0.080 |
Why?
|
Mortality | 1 | 2019 | 2864 | 0.080 |
Why?
|
Biosensing Techniques | 1 | 2013 | 668 | 0.070 |
Why?
|
Prostatectomy | 1 | 2016 | 1890 | 0.070 |
Why?
|
Receptors, Cell Surface | 1 | 2017 | 2866 | 0.070 |
Why?
|
Amyotrophic Lateral Sclerosis | 1 | 2018 | 1414 | 0.070 |
Why?
|
Gene Expression Regulation | 4 | 2011 | 12072 | 0.070 |
Why?
|
Chest Pain | 1 | 2014 | 1114 | 0.070 |
Why?
|
Erythroid Cells | 1 | 2008 | 238 | 0.070 |
Why?
|
Kidney Neoplasms | 1 | 2023 | 4262 | 0.070 |
Why?
|
Fluorescent Dyes | 1 | 2013 | 1917 | 0.070 |
Why?
|
Fluorouracil | 1 | 2010 | 1619 | 0.070 |
Why?
|
DNA Mutational Analysis | 1 | 2014 | 4186 | 0.070 |
Why?
|
Acute Disease | 1 | 2016 | 7149 | 0.070 |
Why?
|
Disease Progression | 3 | 2023 | 13284 | 0.070 |
Why?
|
RNA Interference | 3 | 2017 | 2889 | 0.070 |
Why?
|
Vitamin D Deficiency | 2 | 1992 | 1343 | 0.060 |
Why?
|
Cell Differentiation | 5 | 2010 | 11483 | 0.060 |
Why?
|
Pancreatic Neoplasms | 1 | 2023 | 5256 | 0.060 |
Why?
|
Lymph Nodes | 1 | 2016 | 3474 | 0.060 |
Why?
|
Histone Deacetylase Inhibitors | 1 | 2010 | 789 | 0.060 |
Why?
|
Radiography, Thoracic | 2 | 2023 | 1265 | 0.060 |
Why?
|
Antibodies, Monoclonal | 1 | 2022 | 9274 | 0.060 |
Why?
|
Cisplatin | 1 | 2010 | 1662 | 0.060 |
Why?
|
Cytoplasm | 1 | 2009 | 1539 | 0.060 |
Why?
|
United States | 3 | 2022 | 69872 | 0.060 |
Why?
|
Megakaryocytes | 1 | 2008 | 545 | 0.060 |
Why?
|
Anemia, Diamond-Blackfan | 1 | 2005 | 137 | 0.060 |
Why?
|
Postoperative Care | 1 | 2010 | 1486 | 0.060 |
Why?
|
Erythropoiesis | 1 | 2008 | 705 | 0.060 |
Why?
|
Phenotype | 3 | 2017 | 16365 | 0.060 |
Why?
|
Insulin Resistance | 3 | 1992 | 3864 | 0.060 |
Why?
|
Carrier Proteins | 1 | 2017 | 5021 | 0.060 |
Why?
|
Quality Improvement | 1 | 2018 | 3749 | 0.060 |
Why?
|
Spinal Neoplasms | 1 | 2010 | 760 | 0.060 |
Why?
|
RNA, Messenger | 2 | 2017 | 13033 | 0.060 |
Why?
|
Anti-Bacterial Agents | 1 | 2021 | 7181 | 0.050 |
Why?
|
Silver | 1 | 2023 | 122 | 0.050 |
Why?
|
Thalidomide | 1 | 2008 | 890 | 0.050 |
Why?
|
Odds Ratio | 2 | 2014 | 9849 | 0.050 |
Why?
|
Gene Expression Regulation, Neoplastic | 2 | 2011 | 8428 | 0.050 |
Why?
|
Drug Administration Schedule | 1 | 2010 | 4933 | 0.050 |
Why?
|
Glucose | 2 | 1992 | 4397 | 0.050 |
Why?
|
Gene Regulatory Networks | 1 | 2011 | 1708 | 0.050 |
Why?
|
DNA Repair | 1 | 2011 | 2046 | 0.050 |
Why?
|
Area Under Curve | 2 | 2016 | 1654 | 0.050 |
Why?
|
Cystitis | 1 | 2002 | 93 | 0.050 |
Why?
|
Hospitals, Teaching | 2 | 2021 | 1179 | 0.050 |
Why?
|
Immunologic Memory | 1 | 2008 | 1348 | 0.050 |
Why?
|
Cachexia | 1 | 2023 | 204 | 0.050 |
Why?
|
Genome-Wide Association Study | 1 | 2020 | 12261 | 0.050 |
Why?
|
Particle Accelerators | 1 | 2022 | 173 | 0.050 |
Why?
|
Severity of Illness Index | 2 | 2016 | 15540 | 0.050 |
Why?
|
Organs at Risk | 1 | 2023 | 346 | 0.050 |
Why?
|
Adaptor Proteins, Signal Transducing | 1 | 2011 | 2916 | 0.050 |
Why?
|
Nomograms | 1 | 2022 | 228 | 0.050 |
Why?
|
Protein Processing, Post-Translational | 1 | 2009 | 1990 | 0.050 |
Why?
|
Clindamycin | 1 | 2021 | 139 | 0.050 |
Why?
|
British Columbia | 1 | 2021 | 244 | 0.050 |
Why?
|
Motion | 2 | 2014 | 798 | 0.050 |
Why?
|
Regression Analysis | 1 | 2010 | 6459 | 0.050 |
Why?
|
MicroRNAs | 2 | 2008 | 3752 | 0.050 |
Why?
|
Treatment Failure | 3 | 2015 | 2618 | 0.050 |
Why?
|
Melanoma | 1 | 2019 | 5510 | 0.050 |
Why?
|
Principal Component Analysis | 2 | 2014 | 940 | 0.050 |
Why?
|
Cell Nucleus | 1 | 2009 | 2969 | 0.040 |
Why?
|
Genotype | 1 | 2014 | 12951 | 0.040 |
Why?
|
Myocardial Infarction | 1 | 2021 | 11727 | 0.040 |
Why?
|
Case-Control Studies | 1 | 2017 | 21746 | 0.040 |
Why?
|
Vitamin D | 2 | 1992 | 3223 | 0.040 |
Why?
|
Evolution, Molecular | 1 | 2008 | 1940 | 0.040 |
Why?
|
Forecasting | 1 | 2008 | 2951 | 0.040 |
Why?
|
Risk | 1 | 2011 | 9687 | 0.040 |
Why?
|
Self Administration | 1 | 2000 | 385 | 0.040 |
Why?
|
Tilapia | 1 | 1998 | 24 | 0.040 |
Why?
|
Gene Expression Profiling | 4 | 2011 | 9438 | 0.040 |
Why?
|
Camptothecin | 1 | 2022 | 576 | 0.040 |
Why?
|
Hematopoietic Stem Cells | 2 | 2008 | 3386 | 0.040 |
Why?
|
Workplace | 1 | 2005 | 836 | 0.040 |
Why?
|
Urethral Obstruction | 1 | 2018 | 56 | 0.040 |
Why?
|
Protein Transport | 2 | 2018 | 1988 | 0.040 |
Why?
|
Software | 3 | 2021 | 4443 | 0.040 |
Why?
|
Prednisone | 1 | 2023 | 1574 | 0.040 |
Why?
|
HEK293 Cells | 2 | 2018 | 4204 | 0.040 |
Why?
|
Social Environment | 1 | 2023 | 1023 | 0.040 |
Why?
|
Myelodysplastic Syndromes | 1 | 2008 | 1352 | 0.040 |
Why?
|
Vancomycin | 1 | 2021 | 501 | 0.040 |
Why?
|
Anti-Arrhythmia Agents | 1 | 2022 | 789 | 0.040 |
Why?
|
HeLa Cells | 2 | 2018 | 3128 | 0.040 |
Why?
|
Dexamethasone | 1 | 2005 | 1951 | 0.040 |
Why?
|
Blood Glucose | 1 | 1992 | 6256 | 0.040 |
Why?
|
Epinephrine | 1 | 2020 | 792 | 0.040 |
Why?
|
Health Facilities | 1 | 2022 | 573 | 0.040 |
Why?
|
Skin Tests | 1 | 2019 | 613 | 0.040 |
Why?
|
Heart Failure | 1 | 2021 | 10900 | 0.040 |
Why?
|
Nuclear Proteins | 1 | 2011 | 5853 | 0.040 |
Why?
|
Patient Selection | 1 | 2008 | 4215 | 0.030 |
Why?
|
Infant | 4 | 2022 | 35136 | 0.030 |
Why?
|
Oligonucleotide Array Sequence Analysis | 1 | 2005 | 3920 | 0.030 |
Why?
|
Workflow | 1 | 2021 | 847 | 0.030 |
Why?
|
HCT116 Cells | 1 | 2017 | 408 | 0.030 |
Why?
|
Growth Hormone | 1 | 1998 | 705 | 0.030 |
Why?
|
Child, Preschool | 5 | 2020 | 41006 | 0.030 |
Why?
|
Adenoviridae | 2 | 2014 | 1099 | 0.030 |
Why?
|
Transfection | 2 | 2017 | 5892 | 0.030 |
Why?
|
Electronic Health Records | 2 | 2023 | 4468 | 0.030 |
Why?
|
Social Support | 1 | 2005 | 2118 | 0.030 |
Why?
|
Antigens, Neoplasm | 1 | 2023 | 1988 | 0.030 |
Why?
|
B-Lymphocytes | 1 | 2008 | 4665 | 0.030 |
Why?
|
K562 Cells | 2 | 2008 | 634 | 0.030 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2008 | 4479 | 0.030 |
Why?
|
Primary Prevention | 1 | 2022 | 1167 | 0.030 |
Why?
|
Antigens, CD34 | 2 | 2008 | 657 | 0.030 |
Why?
|
False Positive Reactions | 1 | 2017 | 981 | 0.030 |
Why?
|
Antineoplastic Agents | 1 | 2017 | 13695 | 0.030 |
Why?
|
Transcription, Genetic | 1 | 2008 | 7722 | 0.030 |
Why?
|
Drug Monitoring | 1 | 2000 | 956 | 0.030 |
Why?
|
Analysis of Variance | 2 | 2014 | 6365 | 0.030 |
Why?
|
Bone Marrow Transplantation | 1 | 2002 | 2765 | 0.030 |
Why?
|
Canada | 1 | 2019 | 2065 | 0.030 |
Why?
|
Body Composition | 1 | 2023 | 2401 | 0.030 |
Why?
|
Freezing | 1 | 2013 | 303 | 0.030 |
Why?
|
Immunoglobulin E | 1 | 2019 | 1463 | 0.030 |
Why?
|
Radiography | 2 | 2014 | 7023 | 0.030 |
Why?
|
Immunologic Factors | 1 | 2022 | 1580 | 0.030 |
Why?
|
Learning | 1 | 2022 | 1713 | 0.030 |
Why?
|
Rib Fractures | 1 | 2014 | 131 | 0.030 |
Why?
|
Time | 1 | 2014 | 542 | 0.030 |
Why?
|
Integrases | 1 | 2014 | 533 | 0.030 |
Why?
|
Erythropoietin | 2 | 2008 | 726 | 0.030 |
Why?
|
Body Weight | 1 | 2023 | 4669 | 0.030 |
Why?
|
Lentivirus | 1 | 2014 | 501 | 0.030 |
Why?
|
Glucose Clamp Technique | 1 | 1992 | 266 | 0.030 |
Why?
|
Surgical Wound Infection | 1 | 2021 | 1540 | 0.020 |
Why?
|
Cells, Cultured | 4 | 2008 | 19229 | 0.020 |
Why?
|
AMP-Activated Protein Kinases | 1 | 2014 | 611 | 0.020 |
Why?
|
Stents | 1 | 2023 | 3280 | 0.020 |
Why?
|
Transcription Factors | 1 | 2011 | 12208 | 0.020 |
Why?
|
Hospitalization | 1 | 2010 | 10262 | 0.020 |
Why?
|
Histone Deacetylase 2 | 1 | 2010 | 74 | 0.020 |
Why?
|
Mice, Nude | 1 | 2017 | 3689 | 0.020 |
Why?
|
Inflammation Mediators | 1 | 2019 | 1889 | 0.020 |
Why?
|
Models, Genetic | 1 | 2020 | 3494 | 0.020 |
Why?
|
Coronary Disease | 1 | 2005 | 6077 | 0.020 |
Why?
|
Computer Simulation | 2 | 2014 | 6196 | 0.020 |
Why?
|
Hemorrhage | 1 | 2002 | 3461 | 0.020 |
Why?
|
Proteomics | 1 | 2023 | 3638 | 0.020 |
Why?
|
Protein Array Analysis | 1 | 2011 | 411 | 0.020 |
Why?
|
Receptor Protein-Tyrosine Kinases | 1 | 2017 | 1660 | 0.020 |
Why?
|
Stress, Psychological | 1 | 2005 | 4245 | 0.020 |
Why?
|
Histone Deacetylase 1 | 1 | 2010 | 137 | 0.020 |
Why?
|
Poly(ADP-ribose) Polymerases | 1 | 2011 | 440 | 0.020 |
Why?
|
Injections, Intravenous | 1 | 1992 | 1420 | 0.020 |
Why?
|
Belgium | 2 | 2005 | 103 | 0.020 |
Why?
|
Surgical Procedures, Operative | 1 | 2021 | 1876 | 0.020 |
Why?
|
Ambulatory Care | 1 | 2000 | 2708 | 0.020 |
Why?
|
Animals | 8 | 2018 | 168757 | 0.020 |
Why?
|
Biopsy | 1 | 2021 | 6756 | 0.020 |
Why?
|
Nuclear Localization Signals | 1 | 2009 | 80 | 0.020 |
Why?
|
Feasibility Studies | 2 | 2014 | 5078 | 0.020 |
Why?
|
Models, Biological | 3 | 2014 | 9583 | 0.020 |
Why?
|
Glucose Tolerance Test | 1 | 1992 | 1150 | 0.020 |
Why?
|
Double-Blind Method | 1 | 2023 | 12026 | 0.020 |
Why?
|
Neoplastic Stem Cells | 1 | 2017 | 1376 | 0.020 |
Why?
|
Hospitals, Rural | 1 | 2010 | 172 | 0.020 |
Why?
|
Ventricular Function, Left | 1 | 2021 | 3670 | 0.020 |
Why?
|
Platelet Membrane Glycoprotein IIb | 1 | 2008 | 53 | 0.020 |
Why?
|
Drosophila melanogaster | 1 | 2018 | 1708 | 0.020 |
Why?
|
Adrenal Gland Neoplasms | 1 | 2014 | 740 | 0.020 |
Why?
|
Recurrence | 1 | 2020 | 8340 | 0.020 |
Why?
|
Stroke Volume | 1 | 2021 | 5007 | 0.020 |
Why?
|
Hospitals, Urban | 1 | 2010 | 499 | 0.020 |
Why?
|
Epithelial Cells | 1 | 2020 | 3690 | 0.020 |
Why?
|
Proto-Oncogene Proteins c-myb | 1 | 2008 | 78 | 0.020 |
Why?
|
Africa | 1 | 2010 | 673 | 0.020 |
Why?
|
Hyperparathyroidism | 1 | 1989 | 339 | 0.020 |
Why?
|
Monte Carlo Method | 1 | 2013 | 1254 | 0.020 |
Why?
|
Anthropometry | 1 | 2013 | 1350 | 0.020 |
Why?
|
Integrin beta3 | 1 | 2008 | 122 | 0.020 |
Why?
|
Radiographic Image Enhancement | 1 | 2013 | 885 | 0.020 |
Why?
|
Radon | 1 | 1989 | 81 | 0.020 |
Why?
|
Muscle, Skeletal | 1 | 2023 | 4931 | 0.020 |
Why?
|
Cell Lineage | 2 | 2008 | 2504 | 0.020 |
Why?
|
Kidney | 1 | 2023 | 7186 | 0.020 |
Why?
|
Propensity Score | 1 | 2014 | 1781 | 0.020 |
Why?
|
Child | 4 | 2023 | 77709 | 0.020 |
Why?
|
Carbohydrates | 1 | 1989 | 394 | 0.020 |
Why?
|
Amino Acid Motifs | 1 | 2009 | 936 | 0.020 |
Why?
|
Chromosomes, Human, Pair 5 | 1 | 2008 | 403 | 0.020 |
Why?
|
Microscopy, Fluorescence | 1 | 2013 | 2699 | 0.020 |
Why?
|
Thrombopoietin | 1 | 2008 | 225 | 0.020 |
Why?
|
Acetylation | 1 | 2009 | 1085 | 0.020 |
Why?
|
Molecular Targeted Therapy | 1 | 2017 | 2727 | 0.020 |
Why?
|
Movement | 1 | 2013 | 1471 | 0.020 |
Why?
|
Gene Expression | 2 | 2014 | 7799 | 0.020 |
Why?
|
Mice | 4 | 2017 | 81183 | 0.020 |
Why?
|
Adolescent | 5 | 2018 | 85781 | 0.020 |
Why?
|
Protein Isoforms | 1 | 2010 | 1730 | 0.020 |
Why?
|
Receptor, Insulin | 1 | 1989 | 846 | 0.020 |
Why?
|
Genetic Vectors | 1 | 2014 | 3420 | 0.020 |
Why?
|
Anticoagulants | 1 | 2000 | 4599 | 0.020 |
Why?
|
Stem Cell Factor | 1 | 2005 | 219 | 0.020 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 2 | 2005 | 4751 | 0.020 |
Why?
|
Flow Cytometry | 2 | 2005 | 5974 | 0.020 |
Why?
|
Biological Transport | 1 | 1989 | 2118 | 0.020 |
Why?
|
Lysine | 1 | 2009 | 1007 | 0.020 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2014 | 2948 | 0.010 |
Why?
|
Cytokines | 1 | 2019 | 7322 | 0.010 |
Why?
|
Genes, Reporter | 1 | 2008 | 1547 | 0.010 |
Why?
|
Interleukin-3 | 1 | 2005 | 444 | 0.010 |
Why?
|
Cell Line, Transformed | 1 | 2005 | 898 | 0.010 |
Why?
|
Chromosome Deletion | 1 | 2008 | 1401 | 0.010 |
Why?
|
Luciferases | 1 | 2005 | 733 | 0.010 |
Why?
|
Lymphoma, Non-Hodgkin | 1 | 2010 | 1381 | 0.010 |
Why?
|
Kidney Transplantation | 1 | 1997 | 4251 | 0.010 |
Why?
|
Hodgkin Disease | 1 | 2010 | 1415 | 0.010 |
Why?
|
Retroviridae | 1 | 2005 | 914 | 0.010 |
Why?
|
Quality of Life | 1 | 2023 | 12804 | 0.010 |
Why?
|
Boston | 1 | 2015 | 9313 | 0.010 |
Why?
|
Bone Neoplasms | 1 | 2014 | 2529 | 0.010 |
Why?
|
Research Design | 1 | 2017 | 5987 | 0.010 |
Why?
|
Adenoviridae Infections | 1 | 2002 | 96 | 0.010 |
Why?
|
Genetic Markers | 1 | 2008 | 2634 | 0.010 |
Why?
|
Busulfan | 1 | 2002 | 263 | 0.010 |
Why?
|
BK Virus | 1 | 2002 | 129 | 0.010 |
Why?
|
Intracellular Signaling Peptides and Proteins | 1 | 2011 | 2915 | 0.010 |
Why?
|
Energy Intake | 1 | 1989 | 2148 | 0.010 |
Why?
|
Inflammation | 1 | 2020 | 10638 | 0.010 |
Why?
|
Therapeutic Irrigation | 1 | 2002 | 301 | 0.010 |
Why?
|
Bone Marrow Cells | 1 | 2008 | 2513 | 0.010 |
Why?
|
Recombinant Fusion Proteins | 1 | 2009 | 3772 | 0.010 |
Why?
|
Registries | 1 | 2015 | 8089 | 0.010 |
Why?
|
Antifreeze Proteins | 1 | 1998 | 12 | 0.010 |
Why?
|
Tumor Virus Infections | 1 | 2002 | 452 | 0.010 |
Why?
|
Salmon | 1 | 1998 | 36 | 0.010 |
Why?
|
Databases, Factual | 1 | 2014 | 7729 | 0.010 |
Why?
|
Aquaculture | 1 | 1998 | 25 | 0.010 |
Why?
|
Genetic Predisposition to Disease | 1 | 2020 | 17446 | 0.010 |
Why?
|
Metallothionein | 1 | 1998 | 59 | 0.010 |
Why?
|
International Normalized Ratio | 1 | 2000 | 367 | 0.010 |
Why?
|
Infant, Newborn | 1 | 2018 | 25625 | 0.010 |
Why?
|
Chi-Square Distribution | 1 | 2005 | 3508 | 0.010 |
Why?
|
Neurons | 1 | 2018 | 9338 | 0.010 |
Why?
|
Energy Metabolism | 1 | 1989 | 2899 | 0.010 |
Why?
|
Down-Regulation | 1 | 2005 | 3002 | 0.010 |
Why?
|
Child Development | 1 | 1989 | 2223 | 0.010 |
Why?
|
Risk Assessment | 1 | 2018 | 23338 | 0.010 |
Why?
|
Blotting, Western | 1 | 2005 | 5179 | 0.010 |
Why?
|
Amino Acid Sequence | 1 | 2009 | 13815 | 0.010 |
Why?
|
Pregnancy | 1 | 2018 | 29144 | 0.010 |
Why?
|
Blood Pressure | 1 | 1992 | 8554 | 0.010 |
Why?
|
Long-Term Care | 1 | 2000 | 607 | 0.010 |
Why?
|
Molecular Sequence Data | 1 | 2009 | 18111 | 0.010 |
Why?
|
Disease Models, Animal | 1 | 2014 | 18029 | 0.010 |
Why?
|
Up-Regulation | 1 | 2005 | 4217 | 0.010 |
Why?
|
Glucocorticoids | 1 | 2005 | 2107 | 0.010 |
Why?
|
Fishes | 1 | 1998 | 569 | 0.010 |
Why?
|
Logistic Models | 1 | 2010 | 13408 | 0.010 |
Why?
|
Transplantation Conditioning | 1 | 2002 | 1598 | 0.010 |
Why?
|
Cross-Over Studies | 1 | 2000 | 2029 | 0.010 |
Why?
|
Membrane Proteins | 1 | 2011 | 7880 | 0.010 |
Why?
|
Environmental Exposure | 1 | 1989 | 4234 | 0.010 |
Why?
|
DNA-Binding Proteins | 1 | 2011 | 9648 | 0.010 |
Why?
|
DNA Primers | 1 | 1998 | 2892 | 0.010 |
Why?
|
Homozygote | 1 | 1998 | 1785 | 0.010 |
Why?
|
Signal Transduction | 1 | 2017 | 23403 | 0.010 |
Why?
|
Animals, Genetically Modified | 1 | 1998 | 1549 | 0.010 |
Why?
|
Prevalence | 1 | 2010 | 15226 | 0.010 |
Why?
|
Transplantation, Autologous | 1 | 1997 | 2124 | 0.010 |
Why?
|
Multiple Myeloma | 1 | 2010 | 5181 | 0.010 |
Why?
|
Stem Cells | 1 | 2005 | 3567 | 0.010 |
Why?
|
Decision Making | 1 | 2005 | 3887 | 0.010 |
Why?
|
Cell Line | 1 | 2005 | 15997 | 0.010 |
Why?
|
Glycoproteins | 1 | 1998 | 2263 | 0.010 |
Why?
|
Mice, Inbred C57BL | 1 | 2008 | 21827 | 0.010 |
Why?
|
Patient Education as Topic | 1 | 2000 | 2278 | 0.010 |
Why?
|
Papillomavirus Infections | 1 | 2002 | 1587 | 0.010 |
Why?
|
Sensitivity and Specificity | 1 | 2005 | 14722 | 0.010 |
Why?
|
Colon | 1 | 1997 | 1772 | 0.010 |
Why?
|
Cell Proliferation | 1 | 2005 | 10481 | 0.010 |
Why?
|
Immunosuppressive Agents | 1 | 2002 | 4149 | 0.010 |
Why?
|
Patient Satisfaction | 1 | 2000 | 3396 | 0.000 |
Why?
|
Base Sequence | 1 | 1998 | 12797 | 0.000 |
Why?
|
Promoter Regions, Genetic | 1 | 1998 | 5867 | 0.000 |
Why?
|
Neoplasms, Radiation-Induced | 1 | 1989 | 547 | 0.000 |
Why?
|